TY - JOUR T1 - PTPN3 Could Βe a Therapeutic Target of Pancreatic Cancer JF - Anticancer Research JO - Anticancer Res SP - 2869 LP - 2874 DO - 10.21873/anticanres.15768 VL - 42 IS - 6 AU - HIDEYA ONISHI AU - NAOYA IWAMOTO AU - KEITA SAKANASHI AU - SATOKO KOGA AU - YASUHIRO OYAMA AU - KOSUKE YANAI AU - KATSUYA NAKAMURA AU - SHUNTARO NAGAI AU - AKIKO FUJIMURA AU - KAZUNORI NAKAYAMA AU - KEIGO OZONO AU - AKIO YAMASAKI Y1 - 2022/06/01 UR - http://ar.iiarjournals.org/content/42/6/2869.abstract N2 - Background/Aim: Recently, protein tyrosine phosphatase non-receptor type 3 (PTPN3) has gained attention. However, the role of PTPN3 in cancer has not been fully elucidated. In the present study, we analyzed the role of PTPN3 in pancreatic cancer and investigated whether PTPN3 could be a new therapeutic target for pancreatic cancer. Materials and Methods: Two pancreatic ductal adenocarcinoma (PDAC) cell lines were used as target cells. Cell proliferation was investigated using cell counting and a xenograft mouse model. Migration and invasion were analyzed using Transwell inserts. Activation-related signaling molecules were examined by western blotting. Results: PTPN3 contributes to the proliferation, migration, and invasion of PDAC cells in vitro. PTPN3 promotes tumor growth in a mouse xenograft model, an action mediated partially through the MAPK pathway. Conclusion: PTPN3 could be a new therapeutic target for pancreatic cancer. ER -